Immunovant
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immunovant and other ETFs, options, and stocks.About IMVT
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor.
CEOEric Venker
CEOEric Venker
Employees362
Employees362
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2018
Founded2018
Employees362
Employees362
IMVT Key Statistics
Market cap3.96B
Market cap3.96B
Price-Earnings ratio-7.98
Price-Earnings ratio-7.98
Dividend yield—
Dividend yield—
Average volume1.39M
Average volume1.39M
High today$22.85
High today$22.85
Low today$21.87
Low today$21.87
Open price$22.20
Open price$22.20
Volume1.87M
Volume1.87M
52 Week high$29.49
52 Week high$29.49
52 Week low$12.72
52 Week low$12.72
Stock Snapshot
As of today, Immunovant(IMVT) shares are valued at $22.59. The company's market cap stands at 3.96B, with a P/E ratio of -7.98.
As of 2025-11-23, Immunovant(IMVT) stock has fluctuated between $21.87 and $22.85. The current price stands at $22.59, placing the stock +3.3% above today's low and -1.1% off the high.
The Immunovant(IMVT)'s current trading volume is 1.87M, compared to an average daily volume of 1.39M.
During the past year, Immunovant(IMVT) stock moved between $12.72 at its lowest and $29.49 at its peak.
During the past year, Immunovant(IMVT) stock moved between $12.72 at its lowest and $29.49 at its peak.
Analyst ratings
79%
of 14 ratingsBuy
78.6%
Hold
21.4%
Sell
0%
People also own
Based on the portfolios of people who own IMVT. This list is generated using Robinhood data, and it’s not a recommendation.